Teva Pharmaceutical Industries (TEVA) Projected to Post Quarterly Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) will likely be releasing its earnings data before the market opens on Wednesday, January 29th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.69 per share and revenue of $4,104,790.00 billion for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Teva Pharmaceutical Industries Stock Up 0.6 %

Shares of NYSE:TEVA opened at $21.80 on Tuesday. The stock’s 50-day moving average is $19.74 and its 200 day moving average is $18.41. The company has a market cap of $24.70 billion, a PE ratio of -25.65, a P/E/G ratio of 1.11 and a beta of 0.73. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 1 year low of $11.48 and a 1 year high of $22.80.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on TEVA shares. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.63.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.